Genetic and immunologic susceptibility to statin-related myopathy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Atherosclerosis

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.atherosclerosis.2015.03.025PMID 25818852
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GATM gene variants and statin myopathy risk

  2014cited by this paper
• More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.

  2014cited by this paper
• Statin myotoxicity: a review of genetic susceptibility factors.

  2014cited by this paper
• Pharmacogenomics, Lipid Disorders, and Treatment Options

  2014cited by this paper
• Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2

  2014cited by this paper
• The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• GATM locus does not replicate in rhabdomyolysis study

  2014cited by this paper
• Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.

  2013cited by this paper
• Genetics and Personalized Medicine—a Role in Statin Therapy?

  2013cited by this paper
• Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications.

  2013cited by this paper
• Atorvastatin Treatment Induces Uptake and Efflux Transporters in Human Liver

  2013cited by this paper
• A statin-dependent QTL for GATM expression is associated with statin-induced myopathy

  2013cited by this paper
• Discontinuation of Statins in Routine Care Settings

  2013cited by this paper
• Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.

  2013cited by this paper
• Discontinuation of Statin in Routine Care Settings: A Cohort Study

  2013cited by this paper
• Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

  2013cited by this paper
• SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink

  2013cited by this paper
• Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl‐coenzyme A reductase–associated autoimmune myopathy

  2012cited by this paper
• Statins personalized.

  2012cited by this paper
• Rarity of anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase antibodies in statin users, including those with self‐limited musculoskeletal side effects

  2012cited by this paper
• Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

  2012cited by this paper
• Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial

  2012cited by this paper
• Effect of Statins on Skeletal Muscle Function

  2012cited by this paper
• Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

  2012cited by this paper
• SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia

  2012cited by this paper
• Consortium : CPIC Guideline for SLCO 1 B 1 and Simvastatin-Induced Myopathy

  2012cited by this paper
• Statins as a possible cause of inflammatory and necrotizing myopathies.

  2012cited by this paper
• The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy

  2012cited by this paper
• Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.

  2011cited by this paper
• Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.

  2011cited by this paper
• Abstract 9782: Genetic Variation at the SLCO1B1 Gene Locus and Low Density Lipoprotein Cholesterol Lowering Response to Pravastatin in the Elderly

  2011cited by this paper
• Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study

  2011influential reference
• The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort.

  2011cited by this paper
• Mechanisms of statin-induced myalgia assessed by physiogenomic associations.

  2011influential reference
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• Statin-induced myopathy: a review and update

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• Cerivastatin, genetic variants, and the risk of rhabdomyolysis

  2011cited by this paper
• Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.

  2011cited by this paper
• Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.

  2011cited by this paper
• Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin

  2011cited by this paper
• Immune‐mediated necrotizing myopathy associated with statins

  2010cited by this paper
• Coenzyme Q10: A therapy for hypertension and statin-induced myalgia?

  2010cited by this paper
• Statin myopathy: a review of recent progress

  2010cited by this paper
• Transporter Pharmacogenetics and Statin Toxicity

  2010cited by this paper
• Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.

  2010cited by this paper
• Approach to the patient who is intolerant of statin therapy.

  2010cited by this paper
• The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias

  2010cited by this paper
• The genetics of statin-induced myopathy.

  2010cited by this paper
• A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

  2010cited by this paper
• Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.

  2009cited by this paper
• Pharmacogenomic insights into treatment and management of statin-induced myopathy

  2009cited by this paper
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

  2009cited by this paper
• The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

  2009cited by this paper
• Statin Adverse Effects

  2008cited by this paper
• Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.

  2008cited by this paper
• Prevalence of Musculoskeletal Pain and Statin Use

  2008cited by this paper
• Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation.

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance

  2008cited by this paper
• The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

  2007cited by this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cited by this paper
• The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action

  2007influential reference
• Statin myopathy: Incidence, risk factors, and pathophysiology

  2007cited by this paper
• Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.

  2007cited by this paper
• Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.

  2007cited by this paper
• Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.

  2007cited by this paper
• The role of coenzyme Q10 in statin-associated myopathy: a systematic review.

  2007cited by this paper
• Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.

  2007cited by this paper
• Lipids in Health and Disease

  2007cited by this paper
• The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

  2007cited by this paper
• Physiogenomic association of statin‐related myalgia to serotonin receptors

  2007cited by this paper
• Progressive myopathy with up-regulation of MHC-I associated with statin therapy.

  2007cited by this paper
• Statins provoking MELAS syndrome. A case report.

  2007cited by this paper
• CYP2D6*4 polymorphism is associated with statin-induced muscle effects

  2007cited by this paper
• Statins Provoking MELAS Syndrome

  2007cited by this paper
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

  2006cited by this paper
• SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

  2006cited by this paper
• Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

  2006cited by this paper
• An assessment of statin safety by muscle experts.

  2006cited by this paper
• Genetic risk factors associated with lipid‐lowering drug‐induced myopathies

  2006cited by this paper
• Statin safety: lessons from new drug applications for marketed statins.

  2006cited by this paper
• Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials

  2006cited by this paper
• Abstract 343: Coenzyme Q10 does not Improve Simvastatin Tolerability in Dyslipidemic Patients with Prior Statin-Induced Myalgia

  2006cited by this paper
• Statin safety: an overview and assessment of the data--2005.

  2006cited by this paper
• Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

  2006cited by this paper
• The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment

  2005cited by this paper
• An association study of 43 SNPs in 16 candidate genes with atorvastatin response

  2005cited by this paper
• Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage

  2005cited by this paper
• Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study

  2005cited by this paper
• Genetic Polymorphisms in Cytochrome P450 Enzymes

  2004cited by this paper
• Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions

  2004cited by this paper
• Statin-associated myopathy.

  2003cited by this paper
• Special section on human genetics: With your genes? Take one of these, three times a day

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

  2002influential reference
• ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

  2002cited by this paper

• Case Report: Exercise-associated changes of leukocyte gene expression in statin-associated myopathy

  2025cites this paper
• Increased prevalence and incidence of statin-associated immune-mediated necrotizing myopathy in Native Americans.

  2025cites this paper
• Statin-associated immune-mediated necrotizing myopathy in Hispanic Americans.

  2025cites this paper
• Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

  2025cites this paper
• Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

  2024cites this paper
• Immune-Mediated Necrotizing Myopathy Manifesting after Five Years of Statin Therapy

  2023cites this paper
• Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

  2022cites this paper
• Statin-Induced Necrotizing Autoimmune Myositis

  2022cites this paper
• Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

  2022cites this paper
• SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in south Indian coronary artery disease patients.

  2022cites this paper
• Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence

  2021cites this paper
• Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin

  2019cites this paper
• Pharmacogenetics in Cardiovascular Diseases

  2019cites this paper
• Economic evaluations of a pharmacogenomics test for Statin-induced myopathy in secondary cardiovascular prevention

  2019cites this paper
• Somatosensory amplification, depression, anxiety and pain in statin intolerant patients

  2019cites this paper
• Statin-induced muscular side effects at rest and exercise - An anatomical mapping.

  2019cites this paper
• Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials

  2019cites this paper
• Muscle Toxicity of Drugs: When Medication Turns Physiology into Pathophysiology.

  2019cites this paper
• Muscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure

  2019cites this paper
• Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations

  2018cites this paper
• Genetic and nongenetic factors that may predispose individuals to allergic drug reactions

  2018cites this paper
• Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk

  2018cites this paper
• Statin-induced liver and muscle toxicities

  2018cites this paper
• A comprehensive review and meta-analysis of risk factors for statin-induced myopathy

  2018cites this paper
• Drug-Induced Mitochondrial Toxicity

  2018cites this paper
• Pharmacogenetic implications in the management of metabolic diseases in Brazilian populations

  2018cites this paper
• Myopathies induites par les médicaments

  2017cites this paper
• Pharmacogenetics: a general review on progress to date.

  2017cites this paper
• Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?

  2017cites this paper
• Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium

  2017cites this paper
• Modulation of Systemic Metabolism by MMP-2: From MMP-2 Deficiency in Mice to MMP-2 Deficiency in Patients.

  2016cites this paper
• Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.

  2016cites this paper
• Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK 9 Inhibitors 4

  2016cites this paper
• Running title : Goal-inhibiting statin intolerance

  2016cites this paper
• Expert opinion: the therapeutic challenges faced by statin intolerance

  2016cites this paper
• Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).

  2016cites this paper
• Rationale and design of the SLCO1B1 genotype guided statin therapy trial.

  2016cites this paper
• Association of Statins with Sensory and Autonomic Ganglionopathy

  2015cites this paper
• Management of Dyslipidemia in the Elderly

  2014cites this paper